ACT-335827

ACT-335827

File:ACT-335827.svg

Chemical structure of ACT-335827

ACT-335827 is a chemical compound that has been studied for its potential therapeutic effects. It is primarily known for its role as an antagonist of the orexin receptor, which is involved in the regulation of sleep and wakefulness.

Mechanism of Action

ACT-335827 functions by selectively blocking the activity of the orexin receptors, specifically targeting the orexin-1 receptor (OX1R). Orexin receptors are part of the G protein-coupled receptor family and are activated by the neuropeptides orexin A and orexin B. These receptors play a crucial role in maintaining wakefulness and regulating the sleep-wake cycle.

Potential Therapeutic Uses

Research into ACT-335827 has primarily focused on its potential use in treating sleep disorders such as insomnia and narcolepsy. By inhibiting the orexin-1 receptor, ACT-335827 may help to promote sleep and reduce excessive daytime sleepiness in individuals with these conditions.

Pharmacokinetics

The pharmacokinetic profile of ACT-335827 includes its absorption, distribution, metabolism, and excretion. Studies have shown that it is well-absorbed when administered orally and has a moderate half-life, allowing for potential once-daily dosing.

Research and Development

File:ACT-335827.svg

Another view of the chemical structure

ACT-335827 is currently under investigation in various preclinical and clinical trials to better understand its efficacy and safety profile. These studies aim to determine the optimal dosing regimen and to identify any potential side effects associated with its use.

Related Pages

• Orexin receptor
• Insomnia
• Narcolepsy
• G protein-coupled receptor